Zusammenfassung
Das Korpusmalignom ist in unseren Breiten nach den Malignomen von Brust und Kolorektum der dritthäufigste Krebs der Frau und stellt heute in der Schweiz rund 40 % der weiblichen Genitalmalignome dar [Korpus: 41,2%, Ovar 32,3%, Zervix 18,2%) [Vereinigung Schweizerischer Krebsregister, VSKR,1997]. Im internationalen Vergleich stehen die Schweizer Inzidenzraten, nach den Weißen in Nordamerika, oben in der Rangliste (Abb. 7.1) [Parkin et al.1992].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Aalders J, Abeler V, Kolstad P, Onsrud M (1980) Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Obstet Gynecol 56: 419–427
Aalders JG, Syde RVD, Poppema S, Szabo BG, Janssens J (1984) Prognostic factors and changing trends in the treatment of stage I endometrial cancer: a clinical and histopathological study of 182 patients. Int J Radiat Oncol Biol Phys 10: 2083–2088
Aalders JG, Neijt JP (1993) Aspects of surgery in ovarian and endometrial carcinoma. Eur J Cancer 29A: 624–628
Abayomi O, Dritschilo A, Emami B, Watring WG, Piro AJ (1982) The value of “routine tests” in the staging evaluation of gynecologic malignancies: a cost effectiveness analysis. Int J Radiat Oncol Biol Phys 8: 241–244
Alberts DS, Mason NL, O’Toole RV et al. (1987) Doxorubicincisplatin-vinblastine combination chemotherapy of advanced endometrial carcinoma: a Southwest Oncology Group Study. Gynecol Oncol 26 (2): 193–201
American College of Obstetricians and Gynecologists ACOG (1995) Technical Bulletin. Gynecologic Ultrasonography. p 215
Arrastia CD, Fruchter RG, Clark M et al. (1997) Uterine carcinosarcomas: incidence and trends in management und survival. Gynecol Oncol 65: 158–163
Artner A, Bosze P, Gonda G (1994) The value of ultrasound in preoperative assessment of the myometrial and cervical invasion in endometrial carcinoma. Gynecol Oncol 54: 147–151
Atsukawa H, Sasaki H, Tada S (1994) A multivariate analysis of assessment of myometrial invasion of endometrial carcinoma by magnetic resonance imaging. Gynecol Oncol 54: 298–306
Averette HE, Donato DM, Lovecchio JL, Sevin BU (1987) Surgical staging of gynecologic malignancies. Cancer 60: 2010–2020
Ayoub J, Audet-Lapointe P, Methot Y et al. (1988) Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status. Gynecol Oncol 31: 327–337
Babilonti L, Di Pietro G, La Fianza A, Beretta P, Franchi M (1989) Complications of pelvic lymphadenectomy in patients with endometrial adenocarcinoma. Eur J Gynaecol Oncol 10 (2): 131–133
Backe J, Gassel AM, Krebs S, Caffier H (1997) Prognostic value of immunohistochemic cathepsin D synthesis in endometrial cancer. Geburtshilfe Frauenheilkd 57 (8): 429–434
Baker TR, Piver MS, Lele SB (1988) Stage I uterine adenosarcoma of the uterus: a report of six cases. J Surg Oncol 37: 128–132
Baker TR, Piver MS, Caglar H, Piedmonte M (1991) Prospective trial of cisplatin, adriamycin, and dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary. Am J Clin Oncol 14: 246–250
Ball HG, Blessing JA, Lentz SS, Mutch DG (1996) A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 62 (2): 278–281
Baltzer J, Lohe KJ (1986) Präneoplasien und Karzinome des Endometriums. In: Schmidt-Matthiesen H (Hrsg) Klinik der Frauenheilkunde und Geburtshilfe, Bd 11. Spezielle gynäkolgische Onkologie I. Urban & Schwarzenberg, München, S 231–263
Barakat RR, Wong G, Curtin JP, Vlamis V, Hoskins WJ (1994) Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 55: 164–168
Barakat RR (1995) The effect of tamoxifen on the endometrium. Oncology 9: 129–139
Barrett RJ, Blessing JA, Homesley HD, Twiggs L, Webster KD (1993) Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 16 (6): 494–496
Bauer M (1987) Zur intrakavitären Brachytherapie mit Lang-und Kurzzeit-Afterloading-Technik in der Gynäkologie. Gynäkologie 20: 228–236
Bean HA, Bryant AJS (1978) Carcinoma of the endometrium in Saskatchewan: 1966–1971. Gynecol Oncol 6: 503
Belinson JL, Lee KR, Badger GJ, Pretorius RG, Jorell MA (1992) Clinical stage I adenocarcinoma of the endometrium–analysis of recurrences and the potential benefit of staging lymphadenectomy. Gynecol Oncol 44: 17–23
Bell JG, Minnick A, Reid GC, Judis J, Brownell M (1997) Relationship of nonstaging pathological risk factors to lymph node metastasis and recurrence in clinical stage I endometrial carcinoma. Gynecologic Oncology 66 (3) 388–392
Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL Jr (1988) Treatment of uterine leiomyosarcoma. Obstet Gynecol 71: 845–850
Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL Jr (1990) Treatment of endometrial stromal tumors. Gynecol Oncol 36: 60–65
Berek JS, Hacker NF, Hatch KD, Young RC (1988) Uterine corpus and cervical cancer. Curr Probl Cancer 12 (2): 65
Bhatnagar AS, Batzl C, Häusler A (1996) Pharmacology of nonsteroidal aromatase inhibitors. In: Pasqualini JR, Katzenellenbogen BS (eds) Hormone dependent cancer. Dekker, New York
Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15: 10–17
Bonte J, Ide P, Biliet G, Wynants P (1981) Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma. Gynecol Oncol 11: 140–161
Bornstein J, Auslender R, Pascal B, Gutterman E, Isakov D, Abramovici H (1994) Diagnostic pitfalls of ultrasonographic uterine screening in women treated with tamoxifen. J Reprod Med 39: 674–678
Boronow RC, Morrow CP, Creasman WT, DiSaia PJ, Silverberg SG, Miller A, Blessing JA (1984) Surgical staging in endometrial cancer: clinical-pathological findings of a prospective study. Obstet Gynecol 83: 825–828
Bosscher J, Barnhill D, O’Connor D, Park R (1994) Case report: clinical stage IB endometrial adenocarcinoma with an isolated small bowel metastasis. Gynecol Oncol 52: 99–101
Britton LC, Wilson TO, Gaffey TA, Lieber MM, Wieand HS, Podratz KC (1989) Flow cytometric DNA analysis of stage I endometrial carcinoma. Gynecol Oncol 34: 317–322
Broun GO, Blessing JA, Eddy GL, Adelson MD (1993) A phase II trial of vincristine in advanced or recurrent endometrial carcinoma.A Gynecologic Oncology Group study. Am J Clin Oncol 16: 18–21
Buchsbaum HJ, Lifshitz S, Blythe JG (1979) Prophylactic chemotherapy in stage I and II uterine sarcoma. Gynecol Oncol 8: 346–348
Burke TW, Gershenson DM, Morris M, Stringer CA, Levenback C, Tortolero-Luna G, Baker VV (1994) Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma. Gynecol Oncol 55 (1): 47–50
Butler EB (1976) The early diagnosis of cancer of the endometrium. Clin Obstet Gynecol 3: 389–404
Caduff RF, Johnston CM, Frank TS (1995) Mutations of the K-ras oncogene in carcinoma of the endometrium. Am J Pathol 146: 182
Calero F, Asins-Codoner E, Jimeno J, Rodriguez Escudero F, Mendana J, Iglesias J, Matia F, Armas A, Diaz-Castallanos R, Garzon J (1991) Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Espanol para el Tratamiento Oncologico (GGETO). Eur J Cancer 27: 864–866
Campora E, Vidali A, Mammoliti S, Ragni N, Conte PF (1990) Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide. Eur J Gynaecol Oncol 11 (3): 181–183
Carbone PP, Carter SK (1974) Endometrial cancer: approach to development of effective chemotherapy. Gynecol Oncol 2: 348–353
Carcangiu ML, Chambers JT (1995) Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int J Gynecol Pathol 14: 30–38
Carey MS, O’Connell GJ, Johanson CR et al. (1995) Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarinoma of the endometrium. Gynecol Oncol 57: 138–144
Carlson JA, Allegra IC, Day TG, Wittliff JL (1984) Tamoxifen and endometrial carcinoma: alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia. Am J Obstet Gynecol 149: 149–153
Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML (1996) Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 175: 1195–1200
Chen SS, Spiegel G (1991) Stage I endometrial carcinoma. Role of omental biopsy and omentectomy. J Reprod Med 36: 627–629
Childers JM, Hatch KD, Surwit EA (1992) The role of laparoscopic lymphadenectomie in the management of cervial carcinoma. Gynecol Oncol 47: 38–43
Childers JM, Spirtos NM, Brainard P, Surwit EA (1994a) Laparoscopic staging of the patient with incompletely staged early adenocarcinoma of the endometrium. Obstet Gynecol 83: 497–600
Childers JM (1994b) Operative laparoscopy in gynecological oncology. Baillieres Clin Obstet Gynaecol 8: 831–849
Childers JM, Aqua K, Surwit EA, Hallum A, Hatach K (1994) Abdominal wall tumor implantation following laparoscopy for malignant conditions. Gynecol Oncol 54: 108
Chuang L, Burke TW, Tornos C et al. (1995) Staging laparotomy for endometrial carcinoma: assessment of retroperitoneal lymph nodes. Gynecol Oncol 58: 189–193
Clarke M (1978) Cancer of the endometrium: epidemiology. In: Brush MG, King RJB, Taylor RW (eds) Endometrial cancer. Baillière Tindall, London
Clement PB, Scully RE (1990) Müllerian adenosarcoma of the uterus: a clinicopathologic study of 100 cases with a review of the literature. Hum Pathol 21: 363–381
Clement PB, Oliva E, Young RH (1996) Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions. Int J Gynecol Pathol 15: 222–229
Clifford SL, Kaminetsky CP, Cirisano FD et al. (1997) Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. Am J Obstet Gynecol 176 (6): 229–232
Cohen CJ, Bruckner HW, Deppe G et al. (1984) Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Obstet Gynecol 63: 719–726
Cohen I, Tepper R, Rosen DJ et al. (1995) Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause gravation of endometrial pathologies. Gynecol Oncol 55 /1: 138–143
Coleman MP, Estève J, Damiecki P, Arslan A, Renard H (1993) Trends in cancer incidence and mortality. IARC Sci Publ 121: 455–476
Corn BW, Lanciano RM, Greven KM et al. (1992) Endometrial cancer with paraaortic adenopathy: patterns of failure and opportunity for cure. Int J Radiat Oncol Biol Phys 24: 223–227
Cowles TA, Magrina JF, Masterson BJ, Capen CV (1985) Comparison of clinical and surgical staging in patients with endometrial carcinoma. Obstet Gynecol 66: 413
Creasman WT, Boronow RC, Morrow CP, DiSaia PJ, Blessing J (1976) Adenocarcinoma of the endometrium: its metastatic lymph node potential. Gynecol Oncol 4: 239–243
Creasman WT, McCarty KS, Barton TK (1980) Clinical correlates of estrogen-and progesterone-binding proteins in human endometrial adenocarcinoma. Obstet Gynecol 55: 363–370
Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL (1986) Estrogen replacement therapy in the patients treated for endometrial cancer. Obstet Gynecol 67: 326
Creasman WT, Morrow CP, Bundy L (1987) Surgical pathological spread patterns of endometrial cancer. Cancer 60: 2035
Daniel AG, Peters WA (1988) Accuracy of office and operating room curettage in the grading of endometrial carcinoma. Obstet Gynecol 71: 612
Dargent D (1987) A new future for Schauta’s operation through a presurgical retroperitoneal pelviscopy. Eur J Gynaecol Oncol 8: 292–296
Davids A (1952) Myomectomy, surgical technique and results in a series of 1150 cases. Am J Obstet Gynecol 63: 592–604
De Fusco PA, Gaffey TA, Malkasian GD Jr, Long HJ, Cha SS (1989) Endometrial stromal sarcoma: review of Mayo Clinic experience. Gynecol Oncol 35: 8–14
Descamps P, Calais G, Moire C et al. (1997) Predictors of distant recurrence in clinical stage I oder II endometrial carcinoma treated by combination surgical and radiation therapy. Gynecol Oncol 64: 54–58
Dewar JA, Kerr GR (1985) Value of routine follow up of women treated for early carcinoma of the breast. BMJ 291: 1464–1468
Dinh TV, Slavin RE, Bhagavan BS, Hannigan EV, Tiamson EM, Yandell RB (1989) Mixed Muellerian tumors of the uterus: a clinicopthologic study. Obstet Gynecol 74: 388–392
DiSaia RJ, Creasman WT, Boronow RC, Blessing J (1985) Risk factors and recurrent patterns in stage I endometrial adenocarcinoma. Am J Obstet Gynecol 151: 1009–1014
DiSaia PJ, Creasman WT (1989a) Adenocarcinoma of the uterus. In: DiSaia PJ, Creasman WT (eds) Synopsis of gynecologic oncology. Mosby, St. Louis, pp 161–197
Dorum A, Kristensen GB, Langebrekke A, Sornes T, Skaar O (1993) Evaluation of endometrial thickness measured by endovaginal ultrasound in women with postmenopausal bleeding. Acta Obstet Gyn Scan 72: 116–119
DuBeshter B, Warshal DP, Angej C, Dvoretsky PM, Lin JY, Raubertas RF (1991) Endometrial carcinoma: the relevance of cervical cytology. Obstet Gynecol 77: 458–462
Dunton CJ, Pfeifer SM, Braitman LE, Morgan MA, Carlson JA, Mikuta JJ (1991) Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 41 (2): 113–116
Echt G, Jepson J, Steel J, Langholz B, Luseton G, Hernandez W, Astrahan M, Petrovich Z (1990) Treatment of uterine sarcomas. Cancer 66: 35–39
Edmonson JH, Krook JE, Hilton JF et al. GD (1986) Ineffectiveness of tamoxifen in advanced endometrial carcinoma after failure of progestin treatment. Cancer Treat Rep 70: 1019–1020
Ehrlich CE, Cleary RE, Young PCM (1978) The use of progesterone receptors in the management of recurrent endometrial cancer. In: Brush MG, King RJB, Raylor RW (eds) Endometrial cancer. Baillière-Tindall, London
Elliott P, Green D, Coates A et al. (1994) The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer. Int J Gynecol Cancer 4: 84–93
Emons G, Schally AV (1994) The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod 9: 1364–1379
Emons G, Schulz KD (1995) New developments in the hormonal treatment of endometrial and ovarian cancer. In: Jonat W, Kaufmann M, Munk K (eds) Hormone-dependent tumors. Basic research and clinical studies. Contributions to oncology, vol 50. Karger, Basel, pp 277–298
Enomoto T, Fujita M, Cheng Cet al. (1995) Loss of expression and loss of heterozygosity in the DCC gene in neoplasms of the human female reproductive tract. Br J Cancer 71 (3): 462–467
Fanning J, Tsukada Y, Piver MS (1990) Intraoperative frozen section diagnosis of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol Oncol 37: 47–50
Fanning J, Alvarez PM, Tsukada Y, Piver MS (1991) Prognostic significance of the extent of cervical involvement by endometrial cancer. Gynecol Oncol 40: 46–47
Farhi DC, Nosanchuk J, Silverberg SG (1986) Endometrial adenocarcinoma in women under 25 years of age. Obstet Gynecol 68: 741–745
Farrow GM, Coventry MD, Dockerty MD (1968) Endometrioid sarcoma, “stromal endometriosis”. Am J Obstet Gynecol 100: 301–302
Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM (1994) Endometrial cancer in tamoxifentreated breast cancer patients: findings from the National Surgical adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer I 86: 527–537
Fleischer AC, Kalemeris GC, Machin JE, Entman SS, James AE Jr (1986) Sonographic depiction of normal and abnormal endometrium with histopathologic correlation. J Ultras Med 5: 445–452
Fleischer AC, Dudley BS, Entman SS, Baxter J, Kalemeris GC, James AE Jr (1987) Myometrial invasion by endometrial carcinoma: sonographic assessment. Radiology 162: 307–310
Fleming WP, Peters WA, Kumar NB, Morley GW (1984) Autopsy findings in patients with uterine sarcoma. Gynecol Oncol 19: 168–172
Fornander T, Rutqvist LE, Cedermark B et al. (1989) Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 21: 117–120
Fornander T, Hellstrom AC, Moberger B (1993) Descriptive clinocopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer I 85: 1850–1855
Fournier DV, Junkermann H, Anton HW (1987) Indikation zur Radiotherapie beim Kollum-und Korpuskarzinom nach Operation. Gynäkologe 20: 222–227
Frischkorn R (1983) Die Strahlentherapie des Endometriumkarzinoms. Gynäkologe 16: 104–113
Fujita M, Enomoto T, Ide Y et al. (1994) Expression of CD44 in normal human versus tumor endometrial tissues: possible implications of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res 54: 3922
Gadducci A, Landoni F, Sartori E et al. (1996) Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol 62: 25–32
Gadducci A, Sartori E, Landoni F et al. (1996) Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol 63: 247–253
Gal D, Kopel S, Bashevkin M, Lebowicz J, Lev R, Tancer ML (1991) Oncologie potential of tamoxifen on endometria of postmenopausal women with breast cancer: preliminary report. Gynecol Oncol 42: 120–123
Gallagher CJ, Oliver RTD, Oram DH et al. (1991) A new treatment for endometrial cancer with gonadotropin-releasing hormone analogue. Br J Obstet Gynaec 98: 1037–1041
George M, Pejovic MH, Kramar A, Gynecologic Cooperating Group of French Oncology Centers (1986) Uterine sarcomas: prognostic factors and treatment modalities–study on 209 patients. Gynecol Oncol 24: 58–67
George E, Lillemoe TJ, Twiggs LB, Perrone T (1995) Malignant mixed mullerian tumor versus high grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival. Int J Gynecol Pathol 14: 39–44
Gibson LE, Barakat RR, Venkatraman ES (1996) Endometrial pathology at dilatation and curettage in breast cancer patients: comparison of tamoxifen users and nonusers. Cancer J 2: 35–38
Girardi F, Petru E, Heydarfadai M, Haas J, Winter R (1993) Pelvic lymphadenectomy in the surgical treatment of endometrial cancer. Gynecol Oncol 49: 177–180
Goff BA, Rice LW (1990) Assessment of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol Oncol 38 46–48
Goldstein SR (1990) Incorporating endovaginal ultrasonography into the overall gynecologic examination. Am J Ob-stet Gynecol 612: 625–632
Goldstein SR (1994) Postmenopausal endometrial fluid collections revisited: look at the doughnut rather than the hole. Obstet Gynecol 83: 738–740
Gordon AF, Owen P, Chien PFW, Duncan ID (1997) A critical evaluation of follow-up of women treated for endometrial adenocarcinoma. J Obstet Gynaeco 117, 4386–389
Grady D, Ernster VL (1996) Endometrial cancer. In: Schottenfeld D, Fraumeni JF (eds) Cancer epidemiology and prevention. Oxford University Press, New York, pp 1058–1089
Greven KM, Lanciano EM, Herbert SH, Hogan PE (1991) Analysis of complications in patients with endometrial carcinoma receiving adjuvant irradiation. Int J Radial Oncol Biol Phys 21: 919–923
Grigsby PW, Perez CA, Kuten A et al. (1992) Clinical stage I endometrial cancer: prognostic factors for local control and distant metastasis and implications for the new FIGO surgical staging system. Int J Radiat Oncol Biol Phys 22: 905–911
Haller U, Kubli F, Bräunig G, Müller H, Castano Y, Almendral A (1973) Die diagnostische Aspirationskürettage. Geburtshilfe Frauenheilkd 33: 1–13
Harlow B, Weiss NS, Loften S (1986) The epidemiology of sarcoms of the uterus. J Natl Cancer I 76: 399–402
Hendrickson MR, Ross JC, Kempson RL (1983) Toward the development of morphologic criteria for well-differentiated adenocarcinoma of the endometrium. Am J Surg Pathol 7: 819–838
Hendrickson MR, Longacre TA, Kempson RL (1994) Uterine papillary serous carcinoma revisited. Gynecol Oncol 54: 261–263
Holli K, Hakama M (1989) Effectiveness of routine and spontaneous follow-up visits for breast cancer. Eur J Cancer Clin Oncol 25: 251–254
Hoffman MS, Roberts WS, Cavanagh D, Praphat H, Solomon P, Lyman GH (1989) Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate. Gynecol Oncol 35: 75–77
Hoovis ML (1970) Response of endometrial stromal sarcoma to cyclophosphamide. Am J Obstet Gynecol 108: 1117–1119
Horton J, Begg CB, Arseneault J, Bruckner H, Creech R, Hahn RG (1978) Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat Rep 62 (1): 159–161
Horton J, Elson P, Gordon P, Hahn R, Creech R (1982) Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens. Cancer 49 (12): 2441–2445
Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T (1994) Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium. Gynecol Oncol 55: 144–148
Ingram SS, Rosenman J, Heath R, Morgan TM, Moore D, Varia M (1989) The predictive value of progesterone receptor levels in endometrial cancer. Int J Radiat Oncol Biol Phys 17: 21–27
Iversen OE, Segadal E (1985) The value of endometrial cytology. A comparative study of the Gravlee Jet-Washer, Isaacs cell Sampler and Endoscan versus curettage in 600 patients. Obstet Gynecol Sury 40: 14–20
Janicek MF, Rosenhein NB (1994) Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasy. Gynecol Oncol 52: 373–378
Jones HW (1975) Treatment of adenocarcinoma of the endometrium. Obstet Gynecol Sury 30: 147
Kadar N, Malfetano JH, Homesley HD (1992) Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus: implications for therapy. Obstet Gynecol 80: 655–659
Kahanpaa KV, Wahlstom T, Grohn Pet al. (1986) Sarcoma of the uterus: a clinicopathologic study of 119 patients. Obstet Gynecol 67: 417
Kaku T, Silverberg SG, Major FJ, Miller A, Fetter B, Brady MF (1992) Adenosarcoma of the uterus: a Gynecologic Oncology Group clinicopathologic study of 31 cases. Int J Gynecol Pathol 11: 75–88
Katabuchi H, van Rees B, Lambers AR et al. (1995) Mutations in DNA mismatch repair genes are not responsible for micro-satellite instability for most sporadic endometrial cancers. Cancer Res 55: 5556
Kaunitz AM, Mosciello A, Ostrowski M, Rovira EZ (1988) Comparison of endometrial biopsy with the endometrial pipette and vabra aspirator. J Reprod Med 33: 427–431
Kauppila A, Isotalo HE, Kevinen ST, Vikho RK (1986) Prediction of clinical outcome with estrogen and progestin receptor concentrations and their relationship to clinical and histopathological variables in endometrial cancer. Cancer Res 46: 5380–5384
Kauppila A, Vihko R (1987) Estrogen and progestin receptors as prognostic markers in endometrial cancer. In: Schulz KD, King RJB, Pollow K, Taylor RW (eds) Endometrial cancer. Zuckschwerdt, München, pp 104–111
Kedar RP, Bourne TH, Powles TJ et al. (1994) Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343: 1318–1321
Kilgore LC, Patridge EE, Alvarez RD et al. (1995) Adenocarcinoma of the endometrium: survival comparison of patients with and without pelvic node sampling. Gynecol Oncol 56: 29–33
Kim YB, Niloff JM (1993) Endometrial carcinoma: analysis of recurrence in patients treated with a strategy minimizing lymph node sampling and radiation therapy. Obstet Gynecol 82: 175–180
Kindermann G (1993) Frank Carcinoma. In: Burghardt E (ed) Surgical Gynecologic Oncology. Thieme, Stuttgart, pp 373–376
Köchli OR, Bajka M, Schär G, Schmidt D, Haller U (1995) Invasionstiefenmessung des Korpuskarzinoms. Präoperative Transvaginalsonographie and Korrelation zu intraoperativen and histopathologischen Befunden–eine prospektive Studie. Ultraschall Med 16: 8–11
Köchli OR, Schär GN, Bajka M et al. (1996) Analyse der Indikationen and Resultate der fraktionierten Kürettage an einem großen gynäkologischen Krankengut. Schweiz Med Wschr 126: 69–76
Kohorn EI (1976) Gestagens and endometrial carcinoma. Gynecol Oncol 4 /4: 398–411
Kolstad P (1987) The role or radiation in the treatment of endometrial cancer. In: Schulz KD, King RJB, Pollow K, Taylor RW (eds) Endometrial cancer. Zuckschwerdt, München, pp 129–135
Koss LG, Schreiber K, Oberlander SG, Moukhtar M, Levine HS, Moussouris HF (1981) Screening of asymptomatic women for endometrial cancer. Obstet Gynecol 57: 681–691
Kraus FT (1985) High-risk and premalignant lesions of the endometrium. Am J Surg Pathol 9 (3) (suppl): 31–40
Krieger PD, Gusberg SB (1973) Endolymphatic stromal myosis–a grade I endometrial sarcoma. Gynecol Oncol 1: 299–313
Krebsregister Saarland (1996) Morbidität and Mortalität an bösartigen Neubildungen im Saarland 1993. Statistisches Landesamt Saarland (Sonderhefte 186 )
Kucera H, Vavra N, Weghaupt K (1990) Benefit of external irradiation in pathologic stage I endometrial carcinoma: a prospective clinical trial of 605 patients who received postoperative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors. Gynecol Oncol 38: 99–104
Kullander S (1992) Treatment of endometrial cancer with GnRH-analogs. Recent Results Cancer Res 124: 69–73
Kurman RJ, Norris HJ (1982) Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer 49: 2547–2557
Kurman RJ, Kaminski PF, Norris HJ (1985) The behavior of endometrial hyperplasia. A long-term study of „untreated“ hyperplasia in 170 patients. Cancer 56: 403–412
Kurman RJ, Norris HJ (1994) Endometrial hyperplasia and related cellular changes. In: Kurman RJ (ed) Blaustein’s pathology of the female genital tract. Springer, New York Berlin Heidelberg, pp 411–437
Kurman RJ, Zaino RJ, Norris HJ (1994) Endometrial carcinoma. In: Kurman RJ (ed) Blaustein’s pathology of the female genital tract. Springer, New York Berlin Heidelberg, PP 439–486
Kuten A, Grigsby PW, Perez CA, Fineberg B, Garcia DM, Simpson JR (1989) Result of radiotherapy in recurrent endometrial carcinoma: a retrospective analysis of 51 patients. Int J Radiat Oncol Biol Phys 17: 29–34
Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T (1993) Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 81: 660–664
Lai C, Hsueh S, Chao A, Soong Y (1994) Successful pregnancy after tamoxifen and megestrol acetate therapy for endometrial carcinoma. Br J Obstet Gynaec 101: 547–549
Lampe B, Kurzl R, Hantschmann P (1994) Prognostic factors that predict pelvic lymph node metastasis from endometrial carcinoma. Cancer 74: 2502–2508
Lampe B, Kurzl R, Hantschmann P (1995) Reliability of tumor typing of endometrial carcinoma in prehysterectomy curettage. Int J Gynecol Pathol 14: 2–6
Lanciano RM, Corn BW, Schultz DJ, Kramer CA, Rosenblum N, Hogan WM (1993) The justification for a surgical staging system in endometrial carcinoma. Radiother Oncol 28: 189–196
Lanciano RM, Greven KM (1995) Adjuvant treatment for endometrial cancer: who needs it? Gynecol Oncol 57: 135–137
Larson B, Silfversward C, Nilsson B, Pettersson F (1990) Endometrial stromal sarcoma of the uterus. A clinical and histopathological study–the radiumhemmet series, 1936–1981. Eur J Obstet Gyn RB 35: 239–249
Larson DM, Johnson KK, Reyes CN Jr, Broste SK (1994) Prognostic significance of malignant cervical cytology in patients with endometrial cancer. Obstet Gynecol 84: 399–403
Larson DM, Johnson KK, Broste SK, Krawisz BR, Kresl JJ (1995) Comparison of D&C ad office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol 86: 38–42
Lauritzen C (1987) Exogenous hormones and endometrial carcinogenesis. In: Schulz KD, King RJB, Pollow K, Taylor RW (eds) Endometrial cancer. Zuckschwerdt, München, pp 9–20
Lee RB, Burke TW, Park RC (1990) Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 36: 189–191
Leibsohn S, D’Ablaing G, Mishell DR Jr, Schlaerth JB (1990) Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 162: 968–976
Lessey BA, Albelda S, Buck CA, Castelbaum AJ, Yeh I, Kohler M, Berchuck A (1995) Distributation of integrin cell adhesion molecules in endometrial cancer. Am J Pathol 146 (3): 717–726
Levenback C, Rubin SC, McCormack PM, Hoskins WJ, Atkinson EN, Lewis JL Jr (1992) Resection of pulmonary metastases from uterine sarcomas. Gynecol Oncol 45: 202–205
Levi F, Te VC, Randimbison L (1996) Le cancer dans la population vaudoise 1989–1993. Lausanne Registre vaudois des tumeurs
Levi F, Siegenthaler P, Méan A, Baumann RP, Erler G, Haefliger JM (1997) Registre neuchâtelois des tumeurs. Revue med Suisse rom 117: 537–586
Lewis GC, Slack NH, Mortel R, Bross IDJ (1974) Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer. Gynecol Oncol 2: 368
Lin HH, Chen DC, Chen CK, Chen CL, Chow SN, Huang SC (1995) Is total abdominal hysterectomiy with bilateral salpingo-oophorectomy adequate for new FIGO stage I endometrial carcinoma? Br J Obstet Gynaec 102: 148–152
Lissoni A, Zanetta G, Losa G, Gabriele A, Parma G, Mangioni C (1996) Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 7 (8): 861–863
Lissoni A, Sessa C, Gabriele A, Bonazzi C, Pittelli MR, Marzola M, Mangioni C (1997) Cisplatin, epirubicin and paclitaxel (CEP) in uterine adenocarcinoma. Proceedings of American Society of Clinical Oncology vol. 16:3736 a, 33rd Annual Meeting, May 17–20, Denver, CO
Lissoni A, Cormio G, Colombo N, Gabriele A, Landoni F, Zanetta G, Mangioni C (1997) High-dose epirubicin in patients with advanced or recurrent uterine sarcoma. Int J Gynecol Cancer 7: 241–244
Lohe KJ, Baltzer J, Wolf W, Kürzl R, Tschebiner H (1979) Zur Klinik des Uterussarkoms. Arch Gynecol 228: 651–652
Long HJ et al. (1988) Phase II evaluation of carboplatin in advanced endometrial carcinoma. JNCI 80: 276
Long HJ, Lagdon RM Jr, Cha SS et al. (1995) Phase II trial of methotrexate, vinblastine, doxorubicine, and cisplatin in advanced/recurrent endometrial carcinoma. Gynecol Oncol 58: 240–243
Lovecchio JL, Averette HE, Lichtinger M, Townsend PA, Girtanner RW, Fenton AN (1984) Treatment of advanced or recurrent endometrial adenocarcinoma with cyclophosphamide, doxorubicin, cisplatinum, and megestrol acetate. Obstet Gynecol 63 (4):557–560
Lukes AS, Kohler MF, Pieper CF et al. (1994) Multivariate analysis of DNA ploidy, P53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 73: 2380
Maass H (1987) Epidemiology and etiology. In: Schulz KD, King RJB, Pollow K, Taylor R (eds) Endometrial cancer. Zuckschwerdt, München, pp 3–8
Madej J, Bocian J, Basta A (1985) On the possibility of sparing surgical treatment of leiomyosarcoma in young women, Ginekol Pol 56: 9–12
Magriples U, Naftolin F, Schwartz PE, Carcangiu ML (1993) High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11: 485–490
Major FJ, Blessing JA, Silverberg SG et al. (1993) Prognostic factors in early-stage uterine sarcoma: a Gyncologic Oncology Group study. Cancer 71 (Suppl 4): 1702–1709
Malkasian GD, Annegeres JF, Fountain FS (1980) Carcinoma of the endometrium: stage I. Am J Obstet Gynecol 136: 872–883
Malmstrom H, Schmidt H, Persson PG, Carstensen J, Nordenskjold B, Simonsen E (1992) Flox cytometric analysis of uterine sarcoma: ploidy and s-phase rate as prognostic indicators. Gynecol Oncol 44: 172–177
Malviya VK, Deppe G, Malone JM Jr, Sundareson AS, Lawrence WD (1989) Reliability of frozen section examination in identifying poor prognostic indicators in stage I endometrial adenocarcinoma. Gynecol Oncol 34: 299–304
Malviya VK, Liu PY, O’Toole R et al. (1994) Phase II trial of amonafide in patients with advanced metastatic or recurrent endometrial adenocarcinoma. A Southwest Oncology Group study. Am J Clin Oncol 17 (1): 37–40
Mansi JL, Ramachandra S, Wiltshaw E, Fischer C (1990) Endometrial stromal sarcomas. Gynecol Oncol 36: 113–118
Marchese MJ, Liskow AS, Crum CP, McCaffrey RM, Frick HC (1984) Uterine sarcomas: a clinicopathologic study, 1965–1981. Gynecol Oncol 18: 299–312
Martin R, Lehmann E, Leitsmann H (1990) Hormonrezeptorstatus bei adenomatöser Hyperplasie des Endometriums und Endometriumkarzinom. Zentralbl Gynakol 112: 1031–1038
Matthews RP, Hutchinson-Colas J, Maiman M et al. (1997) Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol Oncol 65 (2): 206–212
Mazur MT, Kurman RJ (1995) Diagnosis of endometrial biopsies and curettings: a practical approach. Springer, New York Berlin Heidelberg, pp 181–183
Mazurka JL, Krepart GV, Lotocki RJ (1988) Prognostic significance of positive peritoneal cytology in endometrial carcinoma. Am J Obstet Gyneco 1158: 303–306
Mestwerdt W, Kranzfelder D (1983) Neue diagnostische Möglichkeiten beim Endometriumkarzinom und seinen Vorstufen. Gynäkologe 16: 87–92
Michalas S, Creatsas G, Deligeoroglou E, Marakaki S (1994) High-grade endometrial stromal sarcoma in a 16-year-old girl. Gynecol Oncol 54: 95–98
Morrow CP, DiSaia PJ, Townsend DE (1973) Current management of endomerial carcinoma. Obstet Gynecol 42: 399
Morrow CP, Townsend DE (1987) Tumors of the endometrium. In: Morrow CP, Townsend DE (eds) Synopsis of gynecologic oncology. Curchill Livingstone, New York, pp 159–205
Morrow CP, Bundy BN, Homesley HD, Creasman WT, Horn-back ND, Kurman R, Thigpen JT (1990) Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II. A Gynecologic Oncology Group Study. Gynecol Oncol 36: 166–171
Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, Graham JE (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40: 55–65
Mouiel J, Crafa F, Cursio R et al. (1995) Oncological risks in laparoscopy surgery. In: Greene F, Rosin R (eds) Minimal ac-ces surgical oncology. Radcliff Medical Press
Murray RML, Pitt P (1984) Treatment of advanced metastatic breast cancer, carcinoma of the prostate and endometrial cancer with aminoglutethimide. In: Nagel GA, Santen RJ (eds) Aminoglutethimide as an aromatase inhibitor in the treatment of cancer. Huber, Bern, pp 109–122
Muss HB, Bundy BN, DiSaia PJ, Homesley HD, Fowler WC, Creasman W,Yordan E (1985) Treatment of recurrent or advanced uterine sarcoma: a randomized trial of doxorubicin versus doxorubicin and cyclophosphamide. A phase III trial of the Gynecologic Oncology Group. Cancer 55: 1648–1653
Muss HB, Blessing JA, Hatch KD, Soper JT, Webster KD, Kemp GM (1990) Methotrexate in advanced endometrial carcinoma: a phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 13: 61–63
Muss HB, Bundy BN, Adcock L, Beecham J (1990) Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 13:32–34
Myeroff LL, Parsons R, Kim SJ et al. (1995) A transforming growth factor b-receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 55: 5545
Neijt JP (1993) Systemic treatment in disseminated endometrial cancer. Eur J Cancer 29A: 628–632
Nezhat C, Burrel M, Nezhat F (1992) Laparoscopic radical hysterectomy with para-aortic and pelvic note dissection. Am J Obstet Gynecol 166: 864–865
Nezhat C, Nezhat F, Teng NNH et al. (1994) The role of laparoscopy in the management of gynecologic malignanc. Seminars in Surgical Oncol 10: 431–439
Norris HJ, Tavassoli FA, Kurman RJ (1983) Endometrial hyperplasia and carcinoma. Diagnostic considerations. Am J Surg Pathol 7: 839–847
Norris HJ, Taylor HB (1966) Mesenchymal tumors of the uterus. I. a clinical and pathological study of 53 endometrial stromal tumors. Cancer 19: 755–766
Olah KS, Gee H, Blunt JA et al. (1991) Retrospective analysis of 318 cases of uterine sarcoma. Eur J Cancer 27: 1095–1099
Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT, Zaino RT (1983) A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52: 626–632
Omura GA, Blessing JA, Major FA (1985) A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 3: 1240–1245
Oriana S, Raspagliesi F, Duca PG (1988) Changes in receptor status after treatment with tamoxifen in endometrial cancer. Int J Biol Markers 3: 233–236
Orr JW Jr, Holloway RW, Orr PF, Holimon JL (1991) Surgical staging of uterine cancer: an analysis of perioperative morbidity. Gynecol Oncol 42: 209–216
Orr JW, Holimon JL, Orr PF (1997) Stage I corpus cancer: is teletherapy necessary. Am J Obstet Gynecol 176: 777–789
Owen P, Duncan I (1996) Is there any value in the long term follow up of women treated for endometrial cancer? Brit J Ob-stet Gynaecol 103: 710–713
Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J (1992) Cancer incidence in five continents, Vol VI. IARC Sci Pub? 120: 964–965
Patchell RA, Tibbs PA, Walsh JW et al. (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322: 494–500
Patridge EE (1991) Endometrial cancer, changing concepts in therapy. Surg Clin North Am 71: 991–1004
Patsner B, Orr JW, Mann WJ (1990) Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma. Am J Obst Gynecol 162: 427–429
Peng-Hui W, Ming-Shyen Y, Chiou-Chung Y et al. (1996) Port site metastasis after laparoscopic-assisted vaginal hysterectomy for endometrial cancer: possible mechanisms and prevention. Gynecol Oncol 66: 151–155
Perez CA, Grigsby PW (1995) Irradiation in the management of carcinoma of the endometrium: a review. Endocurietherapy/Hyperthermia Oncology 11: 67–95
Pettersson F, Kolstad P, Ludwig H, Ulfelder H (1985) Annual report on the results of treatment in gynecological cancer. Radiumhemmet, Stockholm, p 19
Pfleiderer A, Kleine W (1987) Surgical methods and significance of different prognostic criteria. In: Schulz KD, King RJB, Pollow K, Taylor RW (eds) Endometrial cancer. Zuckschwerdt, München, pp 119–135
Pierga JY, Dieras V, Paraiso D et al. (1996) Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin and 5-fluorouracil: a phase II study. Gynecol Oncol 60: 59–63
Pierga JY, Dieras V, Beuzeboc P et al. (1997) Phase II trial of doxorubicin, 5-fluorouracil, etoposide and cisplatin in advanced or recurrent endometrial cancer. Gynecol Oncol 66: 246–249
Pinelli DM, Fiorica JV, Roberts WS, Hoffman MS, Nicosia SV, Cavanagh D (1996) Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma: a phase II study. Gynecol Oncol 6o (3): 462–467
Pitkin RM (1992) Operative laparoscopy: surgical advance or technical gimmick? Obstet Gynecol 79: 144
Pisani AL, Barbuto DA, Chen D, Ramos L, Lagasse LD, Karlan BY (1995) Her-2/neu, p53 and DNA analyses as prognostic factors for survival in endometrial carcinoma. Obstet Gynecol 85: 729
Piver MS, Hempling RE (1990) A prospective trial of postoperative vaginal radium/cesium for grad 1–2 less than 5o% myometrial invasion and pelvic radiation therapy for grade 3 or deep myometrial invasion in surgical stage I endometrial adenocarcinoma. Cancer 66: 1133–1138
Piver MS, Fanning J, Baker TR (1991) Phase II trial of cisplatin, adriamycin, and etoposide for metastatic endometrial adeno carcinoma. Am J Clin Onco 114 (3): 200–202
Pliskow S, Penalver M, Averette HE (1989) Stage III and stage IV endometrial carcinoma: a review of 41 cases. Gynecol Oncol 38: 210–215
Podczaski E, Kaminski P, Gurski K et al. (1992) Detection and patterns of treatment failure in 30o consecutive cases of early endometrial cancer after primary surgery. Gynecol Oncol 47: 323–327
Podratz KC, O’Brien PC, Malkasian GD, Decker DG, Jeffries JA, Edmondson JH (1985) Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 66: 106–110
Potish et al. (1987) Radiation of periaortic node metastases in cancer of the uterine cervix and endometrium. Radiology 165: 567–570
Prussia PR, Clarke HA, Mansoor G, Garriques S (1992) Uterine leiomyosarcoma with intracerebral metastasis: a case report. J Natl Med Assoc 84: 368–370
Pukkala E (1995) Cancer risk by social class and occupation. A survey of 109.000 cases among Finns of working age. Contributions to epidemiology and biostatistics 7. Karger, Basel
Querleu D, Leblanc E, Castelein B (1991) Laparoscopic pelvic lymphadenectomy in the staging of early carcinoma of the cervice. Am J Obstet Gynecol 164: 579–581
Querleu D (1993) Laparoscopic paraaortic lymph node sampling in gynecologic oncology. A preliminary experience. Gynecol Oncol 49: 24–29
Raymond L, Obradovic M, Fioretta G, Droin N, Bouchardy C (1993) Le cancer à Genève: incidence, mortalité, survie 1970–1990. Diréction de la santé publique Genf, les caillers de la santé, No 2
Reddoch JM, Burke TW, Morris M, Tornos C, Levenback C, Gershenson DM (1995) Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme. Gynecol Oncol 59: 221–225
Rendina GM, Donadio C, Fabri M, Mazzoni P, Nazzicone P (1984) Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma. Eur J Obstet Gyn RBI 17: 285–291
Reisinger SA, Staros EB, Mohiuddin M (1991) Survival and failure analysis in stage II endometrial cancer using the revised 1988 FIGO staging system. Int J Radiat Oncol Biol Phys 21: 1027–1032
Richardson GS, MacLaughlin DT (1983) Hormonal receptors in endometrial and ovarian neoplasia. In: Griffiths CT, Fuller AF (eds) Gynecologic Oncology. Martinus Nijhoff, Boston, pp 81–101
Rodriguez GC, Yaqub N, King ME (1993) A comparison of the pipelle device and Vabra Aspirator as measured by endometrial denuclation in hysterectomy specimens; pipelle device samples significantly less of the endometrial surface than the Vabra Aspirator. Am J Obstet Gynecol 168: 55–69
Rose PG, Boutsellis JG, Sachs L (1987) Adjuvant therapy for stage I uterine sarcoma. Am J Obstet Gynecol 156: 660–662
Rose PG, Cha SD, Talc WK, Fitzgerald T, Reale F, Hunter RE (1992) Radiation therapy for surgically proven paraaortic node metastasis in endometrial carcinoma. Int J Radiai Oncol Biol Phys 24: 229–233
Rose PG, Sommers RM, Reale FR, Huner RE, Fournier L, Nelson BE (1994) Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol 84 (1): 12–16
Rose PG, Blessing JA, Lewandowski GS, Creasman WT, Webster KD (1996) A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 63 (1): 101–104
Rosenberg P, Blom R, Hogberg T, Simonsen E (1993) Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma. Gynecol Oncol 51: 311–315
Saffari B, Jones LA, El-Naggar A, Felix JC, George J, Press MF (1995) Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res 55 (23): 5693–5698
Salazar OM, Feldstein ML, de Pappa W, Bonfiglio TA, Keller B, Rubin P, Rudolph J (1977) Endometrial carcinoma: analysis of failures with special emphasis on the use of initial preoperative external pelvic radiation. Int J Radiat Oncol Biol Phys 2: 1101–1107
Salazar OM, Bonfiglio TA, Patten SF, Keller BE, Feldstein ML, Dunne ME, Rudolph JH (1978a) Uterine sarcomas. Analysis of failures with special emphasis on the use of adjuvant radiation therapy. Cancer 42: 1161
Salazar OM, Bonfiglio TA, Patten SF, Keller BE, Feldstein M, Dunne ME, Rudolph JH (1978b) Uterine sarcomas. Natural history, treatment and prognosis. Cancer 42: 1152
Salazar OM, Dunne ME (1980) The role of radiation therapy in the management of uterine sarcomas. Int J Radiat Oncol Bio Phys 6: 899
Samartzis S, Hauser GA (1976) Die Postmenopauseblutung. Geburtsh Frauenheilkd 36: 326–333
Schmidt-Matthiesen H (1987) Endometrium-(Korpus)-Karzinom. In: Schmidt-Matthiesen H, Bastert G (Hrsg) Gynäkologische Onkologie. Schattauer, Stuttgart, S 46–66
Schneider A, Krause N, Kuhne-Heid R, Kamprath S, Endisch U, Merker A, Noschel H (1996) Laparoscopic paraaortic and pelvic lymph node excision–initial experiences and development of a technique. Zentralbl Gynäkol 118 (9): 498–504
Schneider A, Possover M, Kamprath S, Endisch U, Krause N, Noschel H (1996) Laparoscopy assisted radical vaginal hysterectomy modified according to Schauta-Stöckel. Ob-stet Gynecol 88 (6): 1057–1060
Schüler G (1997) Persünliche Mitteilung
Schüler G, Bopp M (1997) Atlas der Krebsmortalität in der Schweiz 1970–1990, Kap C13: Uterus. Birkhäuser, Basel
Schwartz LB, Krey L, Demopoulos R, Goldstein SR, Nachtigal LE, Mittal K (1997) Alterations in steroid hormone receptors in the tamoxifen-treated endometrium. Am J Obstet Gynecol 176: 129–137
Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ (1994) International Histological Classification and Typing of Female Genital Tract Tumours. Springer, New York Berlin Heidelberg
Scurry J, Brand A, Sheehan P, Planner R (1995) High-grade endometrial carcinoma in secretory endometrium in young women: a report of five cases. Gynecol Oncol 60: 224–227
Seski JC, Edwards CL, Gershenson DM, Copeland LJ (1981) Doxorubicin and cyclophosphamide chemotherapy for disseminated endometrial cancer. Obstet Gynecol 58 (1): 88–91
Sevin BU (1986) Primär operative Therapie des Korpuskarzinoms. Gynäkologe 19: 88–93
Sevin BU (1987) Paraaortic lymph node dissection in surgical staging of endometrial carcinoma. In: Takagi S, Friedberg V, Haller U, Knapstein PG, Sevin BU (eds) Gynecologic oncology, surgery and urology. Central Foreign Books, Tokyo, pp 184–189
Sevin BU (1988) Die prätherapeutische Staginglaparotomie. In: Hepp H, Scheidel P, Monaghan JM (Hrsg) Lymphonodektomie in der gynäkologischen Onkologie. Urban & Schwarzenberg, München, S 19–31
Shepherd JH (1989) Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 96: 889–892
Shumsky AG, Stuart GC, Brasher PM, Nation JG, Robertson DI, Sangkarat S (1994) An evaluation of routine follow-up of patients treated for endometrial carcinoma. Gynecol Oncol 55: 229–233
Sievert RM (1937) Two arrangements for reducing dangers in teleradium treatment. Acta Radiol 18: 157–162
Silva EG, Tornos CS, Follen-Mitchell M (1994) Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol 13: 248–258
Silverberg SG, Major FJ, Blessing JA, Fetter B, Askin FB, Liao Sy, Miller A (1989) Carcinosarcoma of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 9 (1): 1–19
Slavic M, Petty WM, Blessing JA, Creasman WT, Homesley HD (1984) Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep 68: 809–811
Slayton RE, Blessing JA, Angel C, Berman M (1987) Phase II trial of etoposide in the management of advanced or recurrent leiomyosarcoma to the uterus: a Gynecologic Oncology Group study. Cancer Treat Rep 71: 1303–1304
Smith MR, Peters WA III, Drescher CW (1994) Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma. Am J Obstet Gynecol 170 (6): 1677–1681
SoodAK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M (1997) Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstetrics and Gynecology 90 (3): 441–447
Spanos WJ, Wharton JT, Gomez L, Fletcher GM, Oswald MS (1984) Malignant mixed mullerian tumors of the uterus. Cancer 53: 311–316
Stoll P, Lutz H, Runnebaum B, Wittlinger H (1977) Gynäkologische Erkrankungen im Klimakterium and im Senium. Deutscher Ärzteverlag, Köln
Styron SL, Burke TW, Linville WK (1989) Low-grade endometrial stromal sarcoma recurring over three decades. Gynecol Oncol 35: 275–278
Sutton G, Blessing JA, Rosenhein N, Photopulos G, DiSaia PJ (1989) Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus, a Gynecologic Oncology Group study. Am J Obstet Gynecol 161: 309–312
Sutton GP, Blessing JA, Barrett RJ, McGehee R (1992) Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 166: 556–559
Sutton GP, Blessing JA, Homesley HD, McGuire WP, Adcock L (1994) Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Cancer 73: 1453–1455
Sutton G, Blessing JA, DeMars LR, Moore D, Burke TW, Grendys EC (1996) A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol 63: 25–27
Sutton G, Blessing JA, Malfetano JH (1996) Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 62: 226–229
Sutton G, Blessing JA, Park R, DiSaia PJ, Rosenshein N (1996) Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group. Obstet Gynecol 87: 747–750
Sutton GP, Blessing JA, Carson LF, Lentz SS, Whitney CW, Gallion HH (1997) Adjuvant ifosfamide, mesna, and cisplatin in patients with completely resected stage I or II carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Proceedings of American Society of Clinical Oncology, Vol 16: 362 a, 33rd Annual Meeting, May 17–20, Denver, CO
Sutton GP, Blessing JA, Ball HG (1997) A phase II study of paclitaxel in patients with advanced or recurrent uterine leiomyosarcomas unexposed to other chemotherapy: a Gynecologic Oncology Group study. Proceedings of American Society of Clinical Oncology, Vol. 16: 366 a, 33rd Annual Meeting, May 17–20, Denver, CO
Swedish Rectal Cancer Trial (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336: 980–987
Taina E, Maenpaa J, Erkkola R, Ikkala J, Soderstrom O, Viitanen A (1989) Endometrial stromal sarcoma: a report of nine cases. Gynecol Oncol 32: 156–162
Thigpen JT, Blessing JA, Lagasse LD, DiSaia PJ, Homesley HD (1984) Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma.A Gynecologic Oncology Group study. Am J Clin Oncol 7 (3): 253–256
Thigpen JT, Blessing J, DiSaia P (1985) Treatment of advanced or recurrent endometrial carcinoma with medroxyprogesterone acetate (MPA): a Gynecologic Oncology Group study. Gynecol Oncol 20: 250
Thigpen JT, Blessing JA, Orr JW Jr, DiSaia PJ (1986) Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study. Cancer Treat Rep 70 (2): 271–274
Thigpen JT, Blessing JA, Wilbanks GD (1986) Cisplatin as second-line therapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 9: 18–20
Thigpen JT, Blessing JA, Homesley H, Creasman WT, Sutton G (1989) Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 33 (1): 68–70
Thigpen JT, Homesley HD (1990) A randomized study of medroxyprogesterone acetate (MPA) zoo mg versus moo mg in the treatment of advanced, persistent or recurrent carcinoma of the endometrium. Gynecologic Oncology Group, Buffalo. In Gynecologic Oncology Group Statistical Report, pp 177
Thigpen JT, Blessing JA, Beecham J, Homesley H, Yordan E (1991) Phase II trial of cisplatin as first line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 9: 1962–1966
Thigpen JT, Blessing J, Homesley H, Malfetano J, DiSaia P, Yordan E (1993) Phase II trial of doxorubicin +/-cisplatin in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 12: 26
Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C (1994) A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 12: 1408–1414
Tinkler SD, Cowie VJ (1993) A review of the Edinburgh experience from 1974 to 1992. Brit J Radiol 66: 98–101
Tornqvist A, Ekelund G, Leandoer L (1982) The value of intensive follow-up after curative resection for colorectal carcinoma. Brit J Surg 69: 725–728
Trope C, Grundsell H, Johnson JE, Cavallin-Stahl E (1980) A phase II study of cisplatinum for recurrent corpus cancer. Eur J Cancer 16: 1025–1026
Trope C, Johnsson JE, Simonsen E, Christiansen H, Cavallin Stahl E, Horvath G (1984) Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin. Am J Obstet Gynecol 149 (4): 379–381
Tseng PC, Sprance HE, Carcangiu ML, Chambers JT, Schwartz PE (1989) CA 125, NB/70 K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma. Obstet Gynecol 74: 384–387
Tsunoda H, Nishida M, Arisawa Y et al. (1996) Adjuvant chemotherapy with cyclophosphamide, adriamycin, and CDDP (CAP) for high risk endometrial cancer after complete surgery. Nippon Sanka Fujinka Gakkai Zasshi 48 (1): 45–51
Van Dinh T, Woodruff JD (1982) Leiomyosarcoma of the uterus. Am J Obstet Gynecol 144: 817–823
van Leeuwen FE, Benraadt J, Coebergh JW et al. (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343: 448–452
van Nagell JR Jr, Hanson MB, Donaldson ES, Gallion HH (1986) Adjuvant vincristine, dactinomycin and cyclophosphamide therapy in stage I uterine sarcomas: a pilot study. Cancer 57: 1451–1454
Vaquero J, Martinez R, El Barkani A, Gomez-Angulo JC, Escardon J (1989) Leiomyosarcoma metastatic to the brain with prolonged survival.J Neurosurg Sci 33: 291–292
Vardi JR, Tadros GH, Anselmo MT, Rafla SD (1992) The value of exploratory laparotomy in patients with endometrial carcinoma according to the new Internatinal Federation of Gynecology and Obstetrics staging. Obstet Gynecol 80: 204–208
Vavra N, Denison U, Kucera H, Barrada M, Kurz C, Salzer H, Sevelda P (1993) Prognostic factors related to recurrent endometrial carcinoma following initial surgery. Acta Obstet Gyn Scan 72: 205–209
Vereinigung Schweizerischer Krebsregister (VSKR) (1997) Rapport d’activitü 1996. Lausanne (Schützung der Krebsneuerkrankungen in der Schweiz)
Wade K, Quinn MA, Hammond I, Williams K, Cauchi M (1990) Uterine sarcoma: steroid receptors and response to hormonal therapy. Gynecol Oncol 39: 364–367
Wheelock JB, Krebs HB, Schneider V, Goplerud DR (1985) Uterine sarcoma: analysis of prognostic variables in 71 cases. Am J Obstet Gynecol 151: 1016–1022
Wolfson AH, Sightler SE, Markoe AM, Schwade JG, Averette HE, Ganjei P, Hilsenbeck SG (1992) The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol 45: 142–146
Wolfson AH, Wolfson DJ, Sittler SY et al. (1994) A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol 52: 56–62
Wronski M, De Palma P, Arbit E (1994) Leiomyosarcoma of the uterus metastatic to brain: a case report and a review of the literature. Gynecol Oncol 54: 237–241
Yamawaki T, Shimizu Y, Hasumi K (1997) Treatment of stage IV “high-grade” endometrial stroma sarcoma with ifosfamid, adriamycin and cisplatin. Gynecol Oncol 64: 265–269
Zaino RJ, Stayaswaroop PG, Mortel R (1985) Hormonal therapy of human endometrial adenocarcinoma in a nude mouse model. Cancer Res 45: 539–541
Zaino RJ, Kurman R, Herbold D, Gliedmann J, Bundy BN, Voet R, Advani H (1991) The significance of squamous differentiation in endometrial carcinoma: data from a Gynecologic Oncology Group study. Cancer 68: 2292–2302
Zaino RJ, Kurman RJ, Diana KL, Morrow CP (1995) The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer 75: 81–86
Zaloudek CI, Norris HJ (1981) Adenofibroma and adenosarcoma of the uterus: a clinicopathologic study of 35 cases. Cancer 48: 354–366
Zaloudek C, Norris HJ (1987) Mesenchymal tumors of the uterus. In: Kurman RJ, Norris HJ (eds) Blaustein’s pathology of the female genital tract. Springer, New York Berlin Heidelberg, pp 371–408
Zaloudek C, Norris H (1994) Mesenchymal tumors of the uterus. In: Kurman RJ (ed) Blaustein’s pathology of the female genital tract. Springer, New York Berlin Heidelberg, pp 488–528
Zorlu CG, Kuscu E, Ergun Y, Aydogdu T, Cobanoglu O, Erdas O (1993) Division of Gynecologic Oncology, Dr. Zekai Tahir Burak Women’s Hospital, Ankara, Turkey. Acta Obstet Gynecol Scand 72 (5): 383–385
Zorlu CG, Kuscu E, Ergun Y, Aydogdu T, Cobanoglu O, Erdas O (1993) Intraoperative evaluation of prognostic factors stage I endometrial cancer by frozen section: how reliable? Acta Obstet Gyn Scan 72: 392–395
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Haller, U., Köchli, O.R., Sevin, BU. (1998). Maligne Tumoren des Corpus uteri. In: Gynäkologische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-58756-6_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-58756-6_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63713-1
Online ISBN: 978-3-642-58756-6
eBook Packages: Springer Book Archive